貨號(hào):A1671259
同義名:
PROTAC IRAK4 degrader-7; KYM-001
KT-474是一種 PROTAC IRAK4 降解劑,顯示出顯著的抗腫瘤效果,通過(guò) IRAK4 靶向降解介導(dǎo)抗癌信號(hào)。


| 規(guī)格 | 價(jià)格 | 會(huì)員價(jià) | 庫(kù)存 | 數(shù)量 | ||||
|---|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} | 咨詢 | 咨詢 |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 現(xiàn)貨 1周 咨詢 | - + |
快速發(fā)貨 順豐冷鏈運(yùn)輸,1-2 天到達(dá)
品質(zhì)保證
技術(shù)支持
免費(fèi)溶解

| 描述 | KT-474是一種強(qiáng)效、選擇性、口服生物利用度良好的IRAK4降解劑。它通過(guò)靶向并促進(jìn)IRAK4蛋白的降解,干預(yù)其在自身免疫疾病中的作用。KT-474展示了在治療包括自身免疫疾病在內(nèi)的各種疾病中的潛力。 |
| 體內(nèi)研究 | 單次口服劑量(75mg, 150mg, 300mg, 600mg, 1000mg, 1600mg)至少6天后,KT-474實(shí)現(xiàn)了深度和劑量依賴性的IRAK4降解。 |
| 體外研究 | KT-474 在人免疫細(xì)胞中表現(xiàn)出對(duì)IRAK4的高選擇性降解,DC50為2.1 nM, DC90為30 nM。 |
| Concentration | Treated Time | Description | References | |
| PBMCs | 200 nM | 16-24 hours | To assess the degradation of IRAK4 in PBMCs. Results showed that KT-474 robustly decreased IRAK4 levels in all immune cell types. | J Invest Dermatol. 2025 Feb;145(2):323-333.e10. |
| Monocytes | 500 nM | 20 hours | To assess the effect of KT-474 on IRAK4 degradation and cytokine production in monocytes. Results showed that KT-474 decreased IRAK4 protein levels and inhibited inflammatory cytokine production. | J Invest Dermatol. 2025 Feb;145(2):323-333.e10. |
| PBMCs | 300 nM | 24 hours | To evaluate the degradation selectivity of KT-474 across the proteome. Results showed that IRAK4 was the only protein significantly downregulated. | J Med Chem. 2024 Oct 24;67(20):18022-18037. |
| PBMCs | 300 nM | 24 hours | To assess the selectivity of KT-474 in human PBMCs. Results showed that KT-474 is selective for IRAK4. | Nat Med. 2023 Dec;29(12):3127-3136. |
| PBMCs | 1 nM (DC50), 30 nM (DC90) | 24, 48, 72, 96 hours | To assess IRAK4 degradation in PBMCs. Results showed maximal degradation of IRAK4 in PBMCs is achieved by 24 hours, with sustained degradation over 96 hours (Max. degradation ~90% compared to DMSO control). | Emily Lurier etal. |
| B cells | 0.12-2000 nM | 16 hours | To assess the inhibitory effect of KT-474 on NF-κB activation in CpG-B stimulated B cells. Results showed that KT-474 inhibited NF-κB activation, whereas PF-06550833 had no effect. | Nat Med. 2023 Dec;29(12):3127-3136 |
| peripheral blood mononuclear cells (PBMCs) | 300 nM | 24 hours | To evaluate the selective degradation of IRAK4 by KT-474. Results showed that KT-474 selectively degraded IRAK4 without affecting other known immune-mediated inflammatory disease substrates. | Nat Med. 2023 Dec;29(12):3127-3136 |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Imiquimod induced mouse model of psoriasis | Oral | 30 mg/kg and 100 mg/kg | Twice a day for 3 days | To assess the anti-inflammatory efficacy of 17 in an imiquimod-induced mouse model of psoriasis. Results showed potent anti-inflammatory efficacy, comparable to topical steroid administration. | J Med Chem. 2024 Oct 24;67(20):18022-18037. |
| 計(jì)算器 | ||||
| 存儲(chǔ)液制備 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.15mL 0.23mL 0.12mL |
5.77mL 1.15mL 0.58mL |
11.55mL 2.31mL 1.15mL |
|
| CAS號(hào) | 2432994-31-3 |
| 分子式 | C44H49F2N11O6 |
| 分子量 | 865.93 |
| SMILES Code | O=C1N(C=2C(=C(C#CCOC3CCN(C[C@H]4CC[C@@H](CC4)N5C=C(NC(=O)C6=C7N(N=C6)C=CC(=N7)N8[C@@]9(C[C@](C8)(OC9)[H])[H])C(C(F)F)=N5)CC3)C=CC2)N1C)C%10C(=O)NC(=O)CC%10 |
| MDL No. | N/A |
| 別名 | PROTAC IRAK4 degrader-7; KYM-001; SAR444656; KT-I-417 |
| 英文名稱 | 5-((1R,4R)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(3-(difluoromethyl)-1-((1r,4R)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)piperidin-1-yl)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| 運(yùn)輸 | 藍(lán)冰 |
| 存儲(chǔ)條件 |
In solvent -20°C: 3-6個(gè)月 -80°C: 12個(gè)月 Pure form Inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO 中的溶解度 : 100 mg/mL (115.48 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響,請(qǐng)使用新開(kāi)封的 DMSO) 以下溶解方案都請(qǐng)先按照體外實(shí)驗(yàn)的方式配制澄清的儲(chǔ)備液,再依次添加助溶劑: ——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議現(xiàn)用現(xiàn)配,當(dāng)天使用; 以下溶劑前顯示的百分比是指該溶劑在終溶液中的體積占比;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的方式助溶
|
滬公網(wǎng)安備 31011002007707號(hào)
滬ICP備2025150922號(hào)-1
危化品經(jīng)營(yíng)許可證:滬(楊)應(yīng)急管危經(jīng)許[2025]204822(QY)
尊敬的 AmBeed 客戶您好,
請(qǐng)您選擇所在區(qū)域,我們將轉(zhuǎn)接對(duì)應(yīng)客服為您服務(wù)!